frontMIND: Phase 3 Study of Tafasitamab Plus Lenalidomide and R-CHOP for Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

In this OncLive Rapid Readout, Nilanjan Ghosh, MD, of Levine Cancer Institute, Atrium Health, reviews phase 3 data evaluating tafasitamab plus lenalidomide and R-CHOP as frontline therapy for adults with newly diagnosed high-risk diffuse large B-cell lymphoma or high-grade B-cell lymphoma. Ghosh explains the rationale for adding the CD19-directed monoclonal antibody tafasitamab and immunomodulatory agent lenalidomide to standard R-CHOP, then outlines the randomized study design, eligibility criteria, treatment arms, and primary end point of progression-free survival. The regimen significantly improved PFS vs R-CHOP alone, with a hazard ratio of 0.75, 2-year PFS of 71% vs 63%, and 3-year PFS of 67% vs 61%. He also discusses subgroup findings, dose delivery, response rates, and safety, including higher cytopenias, gastrointestinal toxicities, and fatal treatment-emergent adverse events during the COVID era, while noting no statistically significant overall survival benefit yet for this potential new treatment option in frontline DLBCL clinical practice today.